FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4309288021> ?p ?o ?g. }

• W4309288021 abstract "The fully human monoclonal antibody erenumab, which targets the calcitonin gene-related peptide (CGRP) receptor, was licensed in Switzerland in July 2018 for the prophylactic treatment of migraine. To complement findings from the pivotal program, this observational study was designed to collect and evaluate clinical data on the impact of erenumab on several endpoints, such as quality of life, migraine-related impairment and treatment satisfaction in a real-world setting.An interim analysis was conducted after all patients completed 6 months of erenumab treatment. Patients kept a headache diary and completed questionnaires at follow up visits. The overall study duration comprises 24 months.In total, 172 adults with chronic or episodic migraine from 19 different sites across Switzerland were enrolled to receive erenumab every 4 weeks. At baseline, patients had 16.6 ± 7.2 monthly migraine days (MMD) and 11.6 ± 7.0 acute migraine-specific medication days per month. After 6 months, erenumab treatment reduced Headache Impact Test (HIT-6™) scores by 7.7 ± 8.4 (p < 0.001), the modified Migraine Disability Assessment (mMIDAS) by 14.1 ± 17.8 (p < 0.001), MMD by 7.6 ± 7.0 (p < 0.001) and acute migraine-specific medication days per month by 6.6 ± 5.4 (p < 0.001). Erenumab also reduced the impact of migraine on social and family life, as evidenced by a reduction of Impact of Migraine on Partners and Adolescent Children (IMPAC) scores by 6.1 ± 6.7 (p < 0.001). Patients reported a mean effectiveness of 67.1, convenience of 82.4 and global satisfaction of 72.4 in the Treatment Satisfaction Questionnaire for Medication (TSQM-9). In total, 99 adverse events (AE) and 12 serious adverse events (SAE) were observed in 62 and 11 patients, respectively. All SAE were regarded as not related to the study medication.Overall quality of life improved and treatment satisfaction was rated high with erenumab treatment in real-world clinical practice. In addition, the reported impact of migraine on spouses and children of patients was reduced.BASEC ID 2018-02,375 in the Register of All Projects in Switzerland (RAPS)." @default.
• W4309288021 created "2022-11-25" @default.
• W4309288021 creator A5003015735 @default.
• W4309288021 creator A5004898085 @default.
• W4309288021 creator A5005018179 @default.
• W4309288021 creator A5010991827 @default.
• W4309288021 creator A5031299902 @default.
• W4309288021 creator A5042031984 @default.
• W4309288021 creator A5059066336 @default.
• W4309288021 creator A5059802195 @default.
• W4309288021 creator A5061396125 @default.
• W4309288021 creator A5065433523 @default.
• W4309288021 creator A5072088379 @default.
• W4309288021 creator A5074642005 @default.
• W4309288021 creator A5075331552 @default.
• W4309288021 creator A5087183247 @default.
• W4309288021 creator A5088333297 @default.
• W4309288021 date "2022-11-18" @default.
• W4309288021 modified "2023-09-30" @default.
• W4309288021 title "Swiss QUality of life and healthcare impact Assessment in a Real-world Erenumab treated migraine population (SQUARE study): interim results" @default.
• W4309288021 cites W1528728629 @default.
• W4309288021 cites W1793427412 @default.
• W4309288021 cites W2014208168 @default.
• W4309288021 cites W204766049 @default.
• W4309288021 cites W2152526535 @default.
• W4309288021 cites W2163438871 @default.
• W4309288021 cites W2163981252 @default.
• W4309288021 cites W2167916207 @default.
• W4309288021 cites W2283260670 @default.
• W4309288021 cites W2325770952 @default.
• W4309288021 cites W2586783269 @default.
• W4309288021 cites W2608751463 @default.
• W4309288021 cites W2762165752 @default.
• W4309288021 cites W2770965214 @default.
• W4309288021 cites W2792811290 @default.
• W4309288021 cites W2801085490 @default.
• W4309288021 cites W2895691305 @default.
• W4309288021 cites W3109638100 @default.
• W4309288021 cites W3185049798 @default.
• W4309288021 cites W3206076334 @default.
• W4309288021 cites W73775937 @default.
• W4309288021 doi "https://doi.org/10.1186/s10194-022-01515-8" @default.
• W4309288021 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36401172" @default.
• W4309288021 hasPublicationYear "2022" @default.
• W4309288021 type Work @default.
• W4309288021 citedByCount "3" @default.
• W4309288021 countsByYear W43092880212022 @default.
• W4309288021 countsByYear W43092880212023 @default.
• W4309288021 crossrefType "journal-article" @default.
• W4309288021 hasAuthorship W4309288021A5003015735 @default.
• W4309288021 hasAuthorship W4309288021A5004898085 @default.
• W4309288021 hasAuthorship W4309288021A5005018179 @default.
• W4309288021 hasAuthorship W4309288021A5010991827 @default.
• W4309288021 hasAuthorship W4309288021A5031299902 @default.
• W4309288021 hasAuthorship W4309288021A5042031984 @default.
• W4309288021 hasAuthorship W4309288021A5059066336 @default.
• W4309288021 hasAuthorship W4309288021A5059802195 @default.
• W4309288021 hasAuthorship W4309288021A5061396125 @default.
• W4309288021 hasAuthorship W4309288021A5065433523 @default.
• W4309288021 hasAuthorship W4309288021A5072088379 @default.
• W4309288021 hasAuthorship W4309288021A5074642005 @default.
• W4309288021 hasAuthorship W4309288021A5075331552 @default.
• W4309288021 hasAuthorship W4309288021A5087183247 @default.
• W4309288021 hasAuthorship W4309288021A5088333297 @default.
• W4309288021 hasBestOaLocation W43092880211 @default.
• W4309288021 hasConcept C126322002 @default.
• W4309288021 hasConcept C159110408 @default.
• W4309288021 hasConcept C1862650 @default.
• W4309288021 hasConcept C2778541695 @default.
• W4309288021 hasConcept C2779951463 @default.
• W4309288021 hasConcept C2780564907 @default.
• W4309288021 hasConcept C2908647359 @default.
• W4309288021 hasConcept C2910587157 @default.
• W4309288021 hasConcept C535046627 @default.
• W4309288021 hasConcept C61943457 @default.
• W4309288021 hasConcept C71924100 @default.
• W4309288021 hasConcept C99454951 @default.
• W4309288021 hasConceptScore W4309288021C126322002 @default.
• W4309288021 hasConceptScore W4309288021C159110408 @default.
• W4309288021 hasConceptScore W4309288021C1862650 @default.
• W4309288021 hasConceptScore W4309288021C2778541695 @default.
• W4309288021 hasConceptScore W4309288021C2779951463 @default.
• W4309288021 hasConceptScore W4309288021C2780564907 @default.
• W4309288021 hasConceptScore W4309288021C2908647359 @default.
• W4309288021 hasConceptScore W4309288021C2910587157 @default.
• W4309288021 hasConceptScore W4309288021C535046627 @default.
• W4309288021 hasConceptScore W4309288021C61943457 @default.
• W4309288021 hasConceptScore W4309288021C71924100 @default.
• W4309288021 hasConceptScore W4309288021C99454951 @default.
• W4309288021 hasIssue "1" @default.
• W4309288021 hasLocation W43092880211 @default.
• W4309288021 hasLocation W43092880212 @default.
• W4309288021 hasLocation W43092880213 @default.
• W4309288021 hasLocation W43092880214 @default.
• W4309288021 hasLocation W43092880215 @default.
• W4309288021 hasLocation W43092880216 @default.
• W4309288021 hasOpenAccess W4309288021 @default.
• W4309288021 hasPrimaryLocation W43092880211 @default.
• W4309288021 hasRelatedWork W1986297116 @default.
• W4309288021 hasRelatedWork W2122311626 @default.

• next